Antigen delivery vectors and constructs
The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
1. A composition comprising:
a fluorocarbon vector-antigen construct of structure C m F n —C y H x -(Sp)-R, where m=3 to 30, n<=2 m+1, y=0 to 15, x<=2y, (m+y)=3-30 and Sp is an optional chemical spacer moiety and R is an immunogenic peptide comprising an antigen; and
one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.
2. The composition of claim 1 , wherein the fluorocarbon vector-antigen construct has a structure
where Sp is an optional chemical spacer moiety and R is an immunogenic peptide comprising an antigen.
3. The composition of claim 1 , wherein the fluorocarbon vector-antigen construct has a structure
where Sp is an optional chemical spacer moiety and R is an immunogenic peptide comprising an antigen.
4. The composition of claim 1 , wherein the fluorocarbon vector-antigen construct has a structure
where Sp is an optional chemical spacer moiety and R is an immunogenic peptide comprising an antigen.
5. The composition of claim 1 , wherein R is an immunogenic peptide comprising an antigen from a virus, a bacteria, a parasite, or an autologous protein, or a cancer antigen.
6. The composition of claim 1 , wherein R comprises one or more epitopes from a viral protein.
7. The composition of claim 1 , wherein R comprises one or more epitopes from a human immunodeficiency virus (HIV) protein.
8. The composition of claim 1 , wherein R is a peptide consisting of between 7 to 70 amino acids.
9. The composition of claim 1 , wherein R comprises at least one B cell epitope.
10. The composition of claim 1 , wherein R comprises two or more overlapping epitopes.
11. The composition of claim 1 , wherein R comprises an HIV epitope.
12. The composition of claim 7 , wherein R comprises one or more HIV env epitopes.
13. The composition of claim 1 , wherein R comprises multiple epitopes and/or fusion peptides.
14. The composition of claim 1 , formulated for parenteral, oral, ocular, rectal, nasal, transdermal, topical, or vaginal administration.
15. The composition of claim 1 , wherein the composition is a liquid, solid, aerosol or gas.
16. The composition of claim 1 , wherein the one or more adjuvants are selected from the group consisting of muramyldipeptide (MDP) derivatives, CpG, monophosphoryl lipid A, oil-in-water adjuvants, water-in-oil adjuvants, aluminium salts, immunostimulating complex (ISCOMs), liposomes, microparticles, saponins, cytokines, or bacterial toxins and toxoids.
17. The composition of claim 5 , wherein the antigen is a viral antigen.
18. The composition of claim 5 , wherein the antigen is a bacterial antigen.
19. The composition of claim 5 , wherein the antigen is a parasitic antigen.
20. The composition of claim 5 , wherein the antigen is a cancer antigen.
21. The composition of claim 1 , wherein the composition comprises a microparticulate adjuvant.
22. The composition of claim 1 , wherein the immunogenic peptide comprises one or more epitopes from an influenza virus.